AB-1001 Gene Therapy ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
8ハンチントン病1

8. ハンチントン病


臨床試験数 : 242 薬物数 : 205 - (DrugBank : 62) / 標的遺伝子数 : 85 - 標的パスウェイ数 : 159
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05541627
(ClinicalTrials.gov)
October 12, 202213/9/2022A Study to Evaluate AB-1001 Striatal Administration in Adults With Early Manifest Huntington's DiseaseAn Open-Label Phase I/II Dose Finding Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Striatal Administration of AB-1001 in Adult Subjects With Early Manifest Huntington's Disease (HD)Huntington DiseaseGenetic: AB-1001 Gene TherapyBrainvectis, a subsidiary of Asklepios BioPharmaceutical, Inc. (AskBio)NULLRecruiting18 Years65 YearsAll18Phase 1/Phase 2France